https://www.benitec.com/for-investors/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_2ac9ccf12c80722bb5d415d65f14b333/benitec/files/theme/images/logo-sm.png /for-investors Equisolve Investor Relations Suite https://www.benitec.com/for-investors/news-events/press-releases/detail/145/benitec-biopharma-to-host-industry-forum-breakfast-event-at-the-2026muscular-dystrophy-association-clinical-and-scientific-conference-on-march-10-2026-highlighting-continued-progress-for-bb-301-the-only-clinical-stage-therapeutic-in-development-for-oculopharyngeal-muscular-dystrophy-opmd Tue, 10 Mar 26 07:00:00 -0400 https://www.benitec.com/for-investors/news-events/press-releases/detail/145/benitec-biopharma-to-host-industry-forum-breakfast-event-at-the-2026muscular-dystrophy-association-clinical-and-scientific-conference-on-march-10-2026-highlighting-continued-progress-for-bb-301-the-only-clinical-stage-therapeutic-in-development-for-oculopharyngeal-muscular-dystrophy-opmd https://www.benitec.com/for-investors/news-events/press-releases/detail/144/benitec-biopharma-announces-positive-interim-phase-1b2a-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-treatment-at-the-2026-muscular-dystrophy-association-clinical-scientific-conference Mon, 09 Mar 26 07:00:00 -0400 https://www.benitec.com/for-investors/news-events/press-releases/detail/144/benitec-biopharma-announces-positive-interim-phase-1b2a-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-treatment-at-the-2026-muscular-dystrophy-association-clinical-scientific-conference https://www.benitec.com/for-investors/news-events/press-releases/detail/143/benitec-biopharma-announces-acceptance-of-late--breaking-abstract-for-the-bb-301-phase-1b2a-clinical-treatment-study-at-the-muscular-dystrophy-association-clinical-scientific-conference Mon, 23 Feb 26 07:00:00 -0500 https://www.benitec.com/for-investors/news-events/press-releases/detail/143/benitec-biopharma-announces-acceptance-of-late--breaking-abstract-for-the-bb-301-phase-1b2a-clinical-treatment-study-at-the-muscular-dystrophy-association-clinical-scientific-conference https://www.benitec.com/for-investors/news-events/press-releases/detail/142/benitec-biopharma-releases-second-quarter-2026-financial-results-and-provides-operational-update Thu, 12 Feb 26 08:30:00 -0500 https://www.benitec.com/for-investors/news-events/press-releases/detail/142/benitec-biopharma-releases-second-quarter-2026-financial-results-and-provides-operational-update https://www.benitec.com/for-investors/news-events/press-releases/detail/141/benitec-biopharma-provides-positive-long-term-clinical-study-results-for-bb-301-phase-1b2a-clinical-trial-demonstrating-robust-efficacy-and-continued-durability-of-response Sun, 11 Jan 26 08:00:00 -0500 https://www.benitec.com/for-investors/news-events/press-releases/detail/141/benitec-biopharma-provides-positive-long-term-clinical-study-results-for-bb-301-phase-1b2a-clinical-trial-demonstrating-robust-efficacy-and-continued-durability-of-response https://www.benitec.com/for-investors/news-events/press-releases/detail/140/benitec-biopharma-releases-first-quarter-2026-financial-results-and-provides-operational-update Fri, 14 Nov 25 17:00:00 -0500 https://www.benitec.com/for-investors/news-events/press-releases/detail/140/benitec-biopharma-releases-first-quarter-2026-financial-results-and-provides-operational-update https://www.benitec.com/for-investors/news-events/press-releases/detail/139/benitec-biopharma-inc-announces-pricing-of-100-million-common-stock-offering Thu, 06 Nov 25 00:19:00 -0500 https://www.benitec.com/for-investors/news-events/press-releases/detail/139/benitec-biopharma-inc-announces-pricing-of-100-million-common-stock-offering https://www.benitec.com/for-investors/news-events/press-releases/detail/138/benitec-biopharma-inc-announces-proposed-public-offering Wed, 05 Nov 25 16:43:00 -0500 https://www.benitec.com/for-investors/news-events/press-releases/detail/138/benitec-biopharma-inc-announces-proposed-public-offering https://www.benitec.com/for-investors/news-events/press-releases/detail/137/benitec-biopharma-provides-positive-interim-clinical-study-results-for-bb-301-phase-1b2a-clinical-trial-and-receives-fda-fast-track-designation-for-bb-301 Mon, 03 Nov 25 07:10:00 -0500 https://www.benitec.com/for-investors/news-events/press-releases/detail/137/benitec-biopharma-provides-positive-interim-clinical-study-results-for-bb-301-phase-1b2a-clinical-trial-and-receives-fda-fast-track-designation-for-bb-301 https://www.benitec.com/for-investors/news-events/press-releases/detail/136/benitec-biopharma-announces-appointment-of-sharon-mates-ph-d-to-its-board-of-directors Mon, 03 Nov 25 07:00:00 -0500 https://www.benitec.com/for-investors/news-events/press-releases/detail/136/benitec-biopharma-announces-appointment-of-sharon-mates-ph-d-to-its-board-of-directors